Tumor Necrosis Factor-α Monoclonal Antibodies in the Treatment of Inflammatory Bowel Disease: Clinical Practice Pharmacology
Tumor Necrosis Factor-α Monoclonal Antibodies in the Treatment of Inflammatory Bowel Disease: Clinical Practice Pharmacology
复制标题
DOI：
10.1016/j.gtc.2010.08.018
复制
发表时间：
2010-09-01
影响因子：
3.7
通讯作者：
Fedorak, Richard N.
中科院分区：
文献类型：
--
作者：
Lee, Thomas W.;Fedorak, Richard N.
在过去的10年里，抗肿瘤坏死因子（TNF）-α治疗已成为自身免疫性疾病治疗的基石临床试验数据一致发现，英夫利昔单抗阿达木单抗和最近的赛妥珠单抗对炎症性肠病患者具有治疗益处（克罗恩病和溃疡性结肠炎）最近对这些单克隆抗体如何在生理和分子水平引起变化的理解提供了对疾病发病机制的见解，并有助于确定未来药物治疗的新靶点。这些抗TNF-α抗体的使用经验增加，长期安全性数据，妊娠期使用已可用。本文概述了目前临床医生治疗克罗恩病和溃疡性结肠炎患者的抗INF-α治疗知识。
In the last 10 years, anti-tumor necrosis factor (TNF)-alpha therapy has become a cornerstone in the management of autoimmune diseases Clinical trial data have consistently found that infliximab adalimumab and recently certolizumab pegol offer therapeutic benefits to patients with inflammatory bowel diseases (Crohn s disease and ulcerative colitis) Recent understanding on how these monoclonal antibodies evoke changes at the physiological and molecular levels have provided insights into disease pathogenesis and helped to identify new targets for future drug therapy With increased experience in the use of these anti-TNF-alpha antibodies the long-term safety data, use in pregnancy have become available This article provides an overview of the current knowledge regarding anti-INF-alpha therapies for clinicians caring for patients with Crohn s disease and ulcerative colitis